Researchers with Biodesix and Genentech presented findings on a test designed to predict response to atezolizumab (Tecentriq) in patients with non-small cell lung cancer.
The blood-based test, which uses expression data from the circulating proteome to classify patients, was found to be predictive for OS and PFS between atezolizumab and docetaxel, the companies said.
Genentech is a member of the Roche Group.
These data suggest a patient’s likelihood of benefiting from PD-L1 checkpoint inhibition can be identified through circulating proteome in blood samples. Researchers presented their findings at the Society for Immunotherapy of Cancer annual meeting in Washington, D.C.
Biodesix test predicts response to atezolizumab in lung cancer
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
THE CLINICAL CANCER LETTER
YOU MAY BE INTERESTED IN
What will happen to biomedical research and health care in the aftermath of the 2024 election? The differences in outcomes couldn’t be more stark.
![](https://cdn.cancerletter.com/media/2024/07/26150614/Harris-4x3-1.jpg)
![](https://cdn.cancerletter.com/media/2024/07/26150614/Harris-4x3-1.jpg)
In the July 19 article “Platinum drugs are off the shortage list, but the underlying problem is unsolved,” FDA Commissioner Robert Califf and others describe a solution to the U.S. drug shortage as a matter of paying more for generic drugs.
![](https://cdn.cancerletter.com/media/2024/07/26150628/story-3-4x3-1-2-768x576.png)
![](https://cdn.cancerletter.com/media/2024/07/26150628/story-3-4x3-1-2-768x576.png)
Cancer treatment is steadily improving. The proof can be found in the number of patients with cancer living longer than ever before. Over the next decade, the number of people who have lived five or more years after their diagnosis is projected to increase approximately 30% to 16.3 million.
![](https://cdn.cancerletter.com/media/2024/07/26150619/Ingram-4x3-1.jpg)
![](https://cdn.cancerletter.com/media/2024/07/26150619/Ingram-4x3-1.jpg)
Tobacco companies have capitalized on the Olympics’ widespread cultural impact since the birth of the modern Olympic Games in 1896—until the practice was stopped in 1987.
![](https://cdn.cancerletter.com/media/2024/07/26150607/archives-4x3-1-1-768x576.png)
![](https://cdn.cancerletter.com/media/2024/07/26150607/archives-4x3-1-1-768x576.png)
Jonathan M. Gerber was named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center.